MEMOUNA FOUDJOU: Open Payments
NPI 1578967972 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,500 in 125 payments from 14 companies in 2025. Trend: 2023 $2,098 · 2024 $3,053 · 2025 $2,500
Food & beverage: $2,500
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 22 | $418 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $404 |
| Teva Pharmaceuticals USA, Inc. | 16 | $383 |
| Alkermes, Inc. | 29 | $366 |
| ABBVIE INC. | 15 | $229 |
| Otsuka America Pharmaceutical, Inc. | 8 | $162 |
| Janssen Pharmaceuticals, Inc | 6 | $155 |
| Supernus Pharmaceuticals, Inc. | 2 | $76 |
| Lundbeck LLC | 3 | $71 |
| Vanda Pharmaceuticals Inc. | 2 | $68 |
Products named: INGREZZA, CAPLYTA, ARISTADA, UZEDY, VRAYLAR, AUSTEDO XR, REXULTI, INVEGA SUSTENNA.
Industry payments across MD — which companies pay providers there.
